These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 22054386

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
    Zhang HL, Ye DW, Yao XD, Dai B, Zhang SL, Shen YJ, Zhu Y, Zhang W.
    Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
    [Abstract] [Full Text] [Related]

  • 3. Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
    Derosa L, Galli L, Orlandi P, Fioravanti A, Di Desidero T, Fontana A, Antonuzzo A, Biasco E, Farnesi A, Marconcini R, Francia G, Danesi R, Falcone A, Bocci G.
    Cancer; 2014 Dec 15; 120(24):3923-31. PubMed ID: 25111199
    [Abstract] [Full Text] [Related]

  • 4. Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.
    Ladoire S, Eymard JC, Zanetta S, Mignot G, Martin E, Kermarrec I, Mourey E, Michel F, Cormier L, Ghiringhelli F.
    Anticancer Res; 2010 Oct 15; 30(10):4317-23. PubMed ID: 21036758
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma.
    Gebbia V, Boussen H, Valerio MR.
    Anticancer Res; 2012 Feb 15; 32(2):529-36. PubMed ID: 22287742
    [Abstract] [Full Text] [Related]

  • 7. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.
    BJU Int; 2012 Oct 15; 110(8):1149-55. PubMed ID: 22369348
    [Abstract] [Full Text] [Related]

  • 8. Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases.
    Yashi M, Nishihara D, Mizuno T, Yuki H, Masuda A, Kambara T, Betsunoh H, Abe H, Fukabori Y, Muraishi O, Kamai T.
    Clin Genitourin Cancer; 2014 Oct 15; 12(5):e197-203. PubMed ID: 24674784
    [Abstract] [Full Text] [Related]

  • 9. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
    Bracarda S, Tonato M, Rosi P, De Angelis V, Mearini E, Cesaroni S, Fornetti P, Porena M.
    Cancer; 2000 Mar 15; 88(6):1438-44. PubMed ID: 10717628
    [Abstract] [Full Text] [Related]

  • 10. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
    Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK, Prostate Cancer Clinical Trials Consortium.
    Cancer; 2008 Feb 01; 112(3):521-6. PubMed ID: 18085595
    [Abstract] [Full Text] [Related]

  • 11. Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
    Barroso-Sousa R, da Fonseca LG, Souza KT, Chaves AC, Kann AG, de Castro G, Dzik C.
    Med Oncol; 2015 Jan 01; 32(1):443. PubMed ID: 25519824
    [Abstract] [Full Text] [Related]

  • 12. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
    Meulenbeld HJ, van Werkhoven ED, Coenen JL, Creemers GJ, Loosveld OJ, de Jong PC, Ten Tije AJ, Fosså SD, Polee M, Gerritsen W, Dalesio O, de Wit R.
    Eur J Cancer; 2012 Nov 01; 48(16):2993-3000. PubMed ID: 22677260
    [Abstract] [Full Text] [Related]

  • 13. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB, Nelson PS, Lin D, Ryan CW, Garzotto M, Beer TM.
    Cancer; 2007 Sep 01; 110(5):996-1002. PubMed ID: 17639587
    [Abstract] [Full Text] [Related]

  • 14. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
    Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ.
    Cancer; 2007 Aug 01; 110(3):556-63. PubMed ID: 17577218
    [Abstract] [Full Text] [Related]

  • 15. Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.
    Trump DL, Payne H, Miller K, de Bono JS, Stephenson J, Burris HA, Nathan F, Taboada M, Morris T, Hubner A.
    Prostate; 2011 Sep 01; 71(12):1264-75. PubMed ID: 21271613
    [Abstract] [Full Text] [Related]

  • 16. A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.
    Beer TM, Ryan C, Alumkal J, Ryan CW, Sun J, Eilers KM.
    Anticancer Drugs; 2010 Apr 01; 21(4):433-8. PubMed ID: 20016365
    [Abstract] [Full Text] [Related]

  • 17. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan.
    Naito S, Tsukamoto T, Koga H, Harabayashi T, Sumiyoshi Y, Hoshi S, Akaza H.
    Jpn J Clin Oncol; 2008 May 01; 38(5):365-72. PubMed ID: 18417502
    [Abstract] [Full Text] [Related]

  • 18. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.
    Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, Bursi S, Allegrini G, Fontana E, Di Marsico R, Antonuzzo A, D'Arcangelo M, Danesi R, Del Tacca M, Falcone A, Bocci G.
    Clin Cancer Res; 2009 Aug 01; 15(15):4954-62. PubMed ID: 19622584
    [Abstract] [Full Text] [Related]

  • 19. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
    Nelius T, Klatte T, Yap R, Kalinski T, Röpke A, Filleur S, Allhoff EP.
    BJU Int; 2006 Sep 01; 98(3):580-5. PubMed ID: 16925757
    [Abstract] [Full Text] [Related]

  • 20. Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study.
    Urakami S, Yoshino T, Kikuno N, Imai S, Honda S, Yoneda T, Kishi H, Shigeno K, Shiina H, Igawa M.
    Urology; 2005 Mar 01; 65(3):543-8. PubMed ID: 15780373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.